Gene Fuller
Family Medicine · Salt Lake City, UTNPI 1396710281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,608 and has fallen 50.7% since, to $792 in 2023.
Across 320 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$587
- Amgen$435
- Pfizer$369
- Sanofi-aventis U.S. LLC$354
- Boehringer Ingelheim$347
- Lilly USA, LLC$301
- plus $3K from 39 others
Across 5 payments — averaging $4614.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$23K
What the payments were for
- Food & beverage$5,170100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,170 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $13,368 |
| Atorvastatin Calcium | 49 | $572 |
| Gabapentin | 13 | $356 |
| Omeprazole | 18 | $325 |
| Levothyroxine Sodium | 29 | $272 |
| Amlodipine Besylate | 28 | $238 |
| Tamsulosin Hcl | 20 | $230 |
| Losartan Potassium | 14 | $156 |
| Lisinopril | 16 | $151 |
| Benazepril Hcl | 11 | $149 |
| Rosuvastatin Calcium | 13 | $146 |
| Simvastatin | 16 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $369 | $13,36814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Mark CacciamaniSalt Lake City$43K
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- David LarsenSalt Lake City$8K
- Michael CobbleSandy$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.